Procedures and Results in Renal Transplantation: Munich Transplant Centre 1986

Conference paper


The presentation in this brochure of different immunosuppressive protocols worked out by different transplant groups may, at first sight, lead to the impression that immunosuppression with Sandimmun is too complex and too confusing, and that there is no ideal way of using Sandimmun optimally that could be recommended by the author. On consideration, however, the reader will detect a firm basic concept which is common to all the immunosuppressive protocols described. In extension of the recommendations already made I should like to outline the immunosuppressive protocols currently used at our centre in Munich, which have proved extremely successful in 1986. The data are given separately for immunological non-high-risk (INHRP) and immunological high-risk patients (IHRP). In this context the definition of IHRP is: 1) patients with preformed antibodies > 30%; 2) patients undergoing retransplantation because the first graft has failed for immunological reasons within a period of 6 months post transplant.


Renal Transplantation Transplant Proc Post Transplant Graft Survival Rate Renal Allograft Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kahan BD (1985) Individualization of Cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 40:457PubMedCrossRefGoogle Scholar
  2. 2.
    Snell SD (1948) Methods for the study of histocompatibility genes. J Genet 49:87PubMedCrossRefGoogle Scholar
  3. 3.
    Stimpfling JH, Durham T (1972) Genetic control by the H-2 gene complex of the alloantibody response to an H-2 antigen. J Immunol 108:947PubMedGoogle Scholar
  4. 4.
    Katz DH, Hamaoka T, Benacerraf B (1973) Cell interactions between histoincompatible T and B lymphocytes. J Exp Med 137:1405PubMedCrossRefGoogle Scholar
  5. 5.
    Balner H (1977) Genetic regions controlling immune responsiveness in primates. Transplant Proc 9:837PubMedGoogle Scholar
  6. 6.
    Woodruff MFA (1960) The transplantation of tissues and organs. Thomas, SpringfieldGoogle Scholar
  7. 7.
    Lechler RI, Batchelor JR (1983) Mechanism of reduced immunogenicity of retransplanted rat kidney allograft. Transplant Proc 15:316Google Scholar
  8. 8.
    Mihatsch MJ, Thiel G, Spichtin HP, Oberholzer M, Brunner FP, Harder F et al. (1983) Morphological findings in kidney transplants after treatment with Cyclosporine. Transplant Proc 15:2821Google Scholar
  9. 9.
    Mihatsch MJ, Thiel G, Basler V, Ryffel B et al. (1985) Morphological pattern in Cyclosporin A-treated renal transplant recipients. Transplant Proc 17:101PubMedGoogle Scholar
  10. 10.
    Pichlmayr R, Wonigeit K, Ringe B, Neuhaus P, Frei K, Offner G, Brodehl J, Mihatsch MJ (1985) A diagnostic and therapeutic approach to minimize nephrotoxicity. In: Sandimmun in renal transplantation. Sandoz, BaselGoogle Scholar
  11. 11.
    Ryffel B, Mihatsch MJ (1987) Cyclosporine Nephrotoxicity: Pathogenic Factors and Prevention. Transplant Proc 19:1635PubMedGoogle Scholar
  12. 12.
    Thiel G, Thorhorst J, Brunner FP (1982) Renal toxicity of Cyclosporin A in the rat. Proc Clin Dial Transplant Forum 10:62Google Scholar
  13. 13.
    Mihatsch MJ, Thiel G, Ryffel B (1986) Morphology of Ciclosporin Nephropathy. Prog Allergy 38:447PubMedGoogle Scholar
  14. 14.
    Sutherland DER, Moudry K (1980) Pancreas Transplant Registry Report. Transplant Proc 18:1739Google Scholar
  15. 15.
    Land W (1987) Immunosuppression for pancreas transplant recipients. In: Dubernard JM, Sutherland DER (eds) Pancreas Transplantation. Nijhoff, Junk, Dordrecht (in preparation)Google Scholar
  16. 16.
    Calne RY, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K (1978) Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet II: 1323CrossRefGoogle Scholar
  17. 17.
    Kahan BD et al. (1984) Impact of mode of pretransplant loading with Cyclosporine on the incidence of early rejection in haplo-identical living-related donor renal recipients. Transplant Proc 16:1619PubMedGoogle Scholar
  18. 18.
    Stiller CR (personal communication)Google Scholar
  19. 19.
    Starzl TE, Iwatsuki S, Shaw BW, Gordon RD, Esquirel C (1986) Liver Transplantation in the Ciclosporin Era. Prog Allergy 38:366PubMedGoogle Scholar
  20. 20.
    Keown PA, Stiller CR, Laupacis AL et al. (1982) The effects and side effects of Cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 14:659PubMedGoogle Scholar
  21. 21.
    Wonigeit K, Hoyer PF, Schumann G, Ringe G, Frei A, Pichlmayr R (1986) Experiences with a blood level-adjusted Cyclosporine regimen in kidney and liver allograft recipients. Transplant Proc 18:181PubMedGoogle Scholar
  22. 22.
    Oyer Ph (personal communication) RIA/HPLC ratio in heart transplantationGoogle Scholar
  23. 23.
    Stiller CR, Stawecki M, Freeman D (1986) Pharmacokinetics of Cyclosporine in solid organ transplantation. Transplant Proc 18:160PubMedGoogle Scholar
  24. 24.
    Quesniaux V (1986) The use of monoclonal antibodies to probe the surface of Cyclosporines. Transplant Proc 18:111PubMedGoogle Scholar
  25. 25.
    Kahan BD, van Buren CT, Lin S et al. (1982) Immunophar-macologic monitoring of Cyclosporin A-treated recipients of cadaveric kidney allografts. Transplantation 34:36PubMedCrossRefGoogle Scholar
  26. 26.
    Wonigeit K (personal communication)Google Scholar
  27. 27.
    Thiel G (personal communication)Google Scholar
  28. 28.
    Keown PA, Stiller CR, Sinclar NR, Carruthers G, Howson W, Stawecki M, McMichael J, Koegler J, McKenzie N, Wall W (1983) The clinical relevance of Cyclosporine blood levels as measured by radioimmunoassay. Transplant Proc 16:2438Google Scholar
  29. 29.
    Land W (1986) Use of Ciclosporin in clinical kidney transplantation. Sandoz Symposium, Osaka, September 1985. International Medical, Tokyo, p 27Google Scholar
  30. 30.
    Heigl F, Castro LA, Hillebrand G, Stoffner D, Schleibner S, Illner W-D, Abendroth D, Land W (1987) Niedrigdosierte Ciclosporin-Behandlung in Kombination mit Methyl - prednisolon und Azathioprin nach Nierentransplantation. Nieren- und Hochdruckkrankheiten (in press)Google Scholar
  31. 31.
    Lokiec F, Poirier O, Gluckman E, Devergie A, Arcese W (1981) A pharmacokinetic study of cyclosporin A: preliminary results. In: Touraine J-L, Gluckman E, Griscelli C (eds) Bone Marrow Transplantation in Europe, Vol 2. Excerpta Medica, Amsterdam, p 160Google Scholar
  32. 32.
    Keown PA, Stiller CR, Klan RA et al. (1981) Immunological and pharmacological monitoring in the clinical use of Ciclosporin A. Lancet 1:686PubMedCrossRefGoogle Scholar
  33. 33.
    Rodgers AJ, Yoshimua N, Kerman RH, Kahan BD (1984) Immunopharmacodynamic evaluation of cyclosporine-treated renal allograft recipients. Transplantation 38:657CrossRefGoogle Scholar
  34. 34.
    Thiel G, Landmann J, Mihatsch MJ (1987) Optimal Use of Sandimmun in Renal Transplantation: The Basle Experience. In: Land W (ed) Optimal Use of Sandimmun® in Organ Transplantation. Springer, Berlin Heidelberg New York London Paris Tokyo, p 25Google Scholar
  35. 35.
    Keown PA (personal communication)Google Scholar
  36. 36.
    Slapak M, Geoghegan T, Digard N, Ahmed K, Sharman VL, Crockett R (1985) The use of low-dose Cyclosporine in combination with Azathioprine and steroids in renal transplantation. Transplant Proc 17:1222Google Scholar
  37. 37.
    Sommer BG, Henry ML, Ferguson RM (1986) Sequential conventional immunotherapy with maintenance Ciclosporine following renal transplantation. Transplant Proc 18:69PubMedGoogle Scholar
  38. 38.
    Sollinger HW, Deierhoi M, Kalayoglu M, Beizer FO (1986) Sequential Antilymphocyte Globulin Cyclosporine in Cadaveric Renal Transplantation. Transplant Proc 18:16PubMedGoogle Scholar
  39. 39.
    Hillebrand G, Castro LA, Illner W-D, Schleibner S, Heigl F, Gurland HJ, Land W (1986) Immunsuppressive 4fach-Kombination nach Nierentransplantation: Erste Erfahrungen bei immunologischen Risikopatienten. II. Ciclosporin Symposium Hannover/FRGGoogle Scholar
  40. 40.
    McGregor ChGA, Oyer PhE, Shumway NE (1986) Heart and heart-lung transplantation. Prog Allergy 38:346PubMedGoogle Scholar
  41. 41.
    European Multicentre Trial Group (1983) Cyclosporin in cadaveric renal transplantation. One year follow-up. Lancet 11:986CrossRefGoogle Scholar
  42. 42.
    Kahan BD, Flechner SM, Lorber MI, Golden D, Conley S, van Buren CT (1987) Complications of Cyclosporin-Prednisolone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for one to five years. Transplantation (in press)Google Scholar
  43. 43.
    Canafax DM, Simmons RL, Sutherland DER, Fryd DS, Strand MH, Ascher NL, Payne WD, Najarian JS (1986) Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: Results of the Minnesota randomized trial comparing Cyclosporine versus Antilymphocyte Globulin - Azathioprine. Transplant Proc 18:192PubMedGoogle Scholar
  44. 44.
    Wood RFM, Thompson JF, Ting A, Benjamin IS, Allen NH, Morris PJ (1985) A randomized controlled trial of short-term Cyclosporin therapy in renal transplantation (Trial II). Transplant Proc 17:1164Google Scholar
  45. 45.
    Vanrenterghem Y, Waer M, Michieisen P (1985) A controlled trial of one versus three months’ Cyclosporine and conversion to Azathioprine in renal transplantation. Transplant Proc 17:1162Google Scholar
  46. 46.
    Land W, Castro LA, Hillebrand G, Günther K, Gokel JM (1983) Conversion rejection consequences by changing the immunosuppressive therapy from Cyclosporin to Azathioprine after kidney transplantation. Transplant Proc 15:2857Google Scholar
  47. 47.
    Keown PA, Stiller CR (unpublished results)Google Scholar
  48. 48.
    Hall BM (1986) Australian multicentre trial of short and long term Cyclosporin A, compared to conventional therapy in renal transplantation. XI. International Congress of the Transplantation Society, Helsinki 1986. Abstract volume, p 19, 1Google Scholar
  49. 49.
    Keown PA, Stiller CR (in preparation) Conversion from Cyclosporine to alternative immunosuppression following renal transplantationGoogle Scholar
  50. 50.
    Sells R (1986) (personal communication)Google Scholar
  51. 51.
    Starzl TE, Weil R III, Iwatsuki S (1980) The use of Cyclosporin A and prednisolone in cadaver kidney transplantation. Surg Gynecol Obstet 151:17PubMedGoogle Scholar
  52. 52.
    Flechner SM, Kerman RH, van Buren CT, Epps L, Kahan BD 1984 The use of Cyclosporine in living-related renal transplantation: Donor-specific hyporesponsiveness and steroid withdrawal. Transplantation 38:685PubMedCrossRefGoogle Scholar
  53. 53.
    Land W (1986) Aktuelle Aspekte der Transplantationsmedizin. MMW 128:878Google Scholar
  54. 54.
    Slapak M, Shell T, Digard N, Gosling DC, Rovera G, Crockett RC, Ahmed K (1987) Triple and quadruple therapy after renal transplantation in patients from developing countries. Transplant Proc 19:1922PubMedGoogle Scholar
  55. 55.
    Hillebrand G, Castro LA, Habersetzer R, Steitz H-O, Illner W-D, Land W (1987) Immunsuppressive 4fach-Kombination nach Nierentransplantation (NT). Risiko und Nutzen bei immunologisch gefährdeten Patienten. Klin Wochenschr 65 [Suppl IX]: 133Google Scholar
  56. 56.
    Simmons RL, Canafax DM, Fryd DS, Ascher NL, Payne WD, Sutherland DER, Najarian JS (1982) New immunosuppressive drug combinations for mismatched related and cadaveric renal transplantation. Transplant Proc 18:76Google Scholar
  57. 57.
    Cabrol C, Garidjbakheh I, Parie A, Cabrol A, Corcos T, Mattei MF, Lefer Ph, Vayssier E, Rottenbourg J, Aupetit B (1986) Indications and Contraindications for Cardiac Transplantation: New Trends in Immunosuppressive Therapy and Results. Transplant Proc 18:35Google Scholar
  58. 58.
    Starzl TE (personal communication)Google Scholar
  59. 59.
    Pichlmayr R, Ringe B, Lauckart W, Wonigeit K (1987) Liver transplantation. Transplant Proc 19:103PubMedGoogle Scholar
  60. 60.
    St Cyr JA, Elick BA, Freeze D, Sharp H, Payne W, Bloomer J etal. (1987) Use of triple therapy and percutaneous needle biopsy to minimize rejection following liver transplantation. Transplant Proc 19:2451PubMedGoogle Scholar
  61. 61.
    Sollinger H (personal communication)Google Scholar
  62. 62.
    Tyden G, Brattström C, Gunnarsson R, Lundgren G, Öst L, Ostmann J, Groth CG (1987) Metabolic control 4 months to 4 years after pancreatic transplantation with special reference to the role of Cyclosporin. Transplant Proc 19:2294PubMedGoogle Scholar
  63. 63.
    Land W, Illner W-D, Abendroth D, Landgraf R (1986) Pancreas transplantation in diabetics in 1986 — the Munich experience. Eurotransplant Meeting, September 1986. Abstract volumeGoogle Scholar
  64. 64.
    Sutherland DER (personal communication)Google Scholar
  65. 65.
    Sollinger H, Kalayoglu M, Hofmann RM, Deierhoi M, Beizer FO (1987) Quadruple immunosuppressive therapy in whole pancreas transplantation. Transplant Proc 19:2297PubMedGoogle Scholar
  66. 66.
    Margreiter R (1986) Invited comment on clinical pancreatic transplantation. Eurotransplant Meeting, September 1986. Abstract volumeGoogle Scholar
  67. 67.
    Kahan BD, Lorber MI, Flechner SM, van Buren CT, Jensen J, Wideman CA (1986) Comparison of five Cyclosporine-Prednisone regimens for induction of immunosuppression in cadaveric kidney recipients: A retrospective analysis of 245 cases. Transplant Proc 18:59PubMedGoogle Scholar
  68. 68.
    McDonald AS (1986) Randomized study of Cyclosporin with and without prednisone in renal allograft recipients. XI. International Congress of the Transplantation Society, Helsinki 1986. Abstract volume, poster presentation, p 34, 14Google Scholar
  69. 69.
    Lundgren G, Albrechtsen D, Brynger H, Flatmark A, Frödin L, Gabel H, Persson H, Thorsby E, Groth CG (1987) Improved early course after cadaveric renal transplantation by reducing the Cyclosporin dose and adding Azathioprine. Transplant Proc 19:2074PubMedGoogle Scholar
  70. 70.
    Kahan BD (personal communication)Google Scholar
  71. 71.
    Bergstrand A, Bohmann SO, Farnsworth A, Gokel JM, Krause PH, Larig W, Mihatsch MJ, Oppedal B, Sell S, Sibley RK, Thiru S, Verani R, Wallace AC, Zollinger HU, Ryffel B, Thiel G, Wonigeit K (1985) Renal histopathology in kidney transplant recipients immunosuppressed with Ciclosporin A. Clin Nephrol 24:107Google Scholar

Copyright information

© Sandoz Ltd, Basle and Springer-Verlag, Berlin Heidelberg 1987

Authors and Affiliations

  • W. Land

There are no affiliations available

Personalised recommendations